HM15211 vs Lixisenatide
Head-to-head comparison of HM15211 (HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | HM15211 | Lixisenatide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | HM15211, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist | Exendin-4-derived GLP-1 receptor agonist |
| Molecular Weight | N/A | 4858 Da |
| Half-Life | Approximately 1 week | 2-4 hours |
| Amino Acids | N/A | 44 |
| Typical Dose | Investigational; no established human dose | 10-20 mcg daily |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 12 | 400 |
| Research Status | Clinical | Approved |
HM15211 Benefits
- ✓appetite suppression
- ✓greater fat oxidation
- ✓weight loss
- ✓improved metabolic markers
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
HM15211 Dosing
once-weekly subcutaneous injection|titration to effect|maintenance at tolerated dose
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
HM15211 Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠reduced appetite
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Research Overview
HM15211
Research has shown potent weight-reducing and metabolic effects in preclinical and translational studies. The compound is being developed as a next-generation incretin-based therapy.
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.